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Abstract 12 
A protocol was defined which utilised peptides as probes for the characterisation of reversed phase 13 
chromatography peptide separation systems. These peptide probes successfully distinguished 14 
between differing stationary phases through the probe’s hydrophobic, electrostatic, hydrogen 15 
bonding and aromatic interactions with the stationary phase, in addition, to more subtle interactions 16 
such as the phase’s ability to separate racemic or isomeric probes.  17 
The dominating forces responsible for the chromatographic selectivity of peptides appear to be 18 
hydrophobic as well as electrostatic and polar in nature. This highlights the need for other types of 19 
stationary phase ligands with possibly mixed mode functionalities / electrostatic / polar interactions 20 
for peptide separations rather than the hydrophobic ligands which dominate small molecule 21 
separations. Selectivity differences are observed between phases, but it appears that it is the 22 
accessibility differences between these phases which play a crucial role in peptide separations i.e. 23 
accessibility to silanols, the hydrophobic acetonitrile / ligand layer or a thin adsorbed water layer on 24 
the silica surface.  25 
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1 Introduction 30 
The biopharmaceutical industry is an expanding global market with a substantially increased market 31 
share over recent years [1-2]. Many pharmaceutical companies are now investing significant 32 
resources into developing biomolecules, which is a complex as well as expensive process. Peptides 33 
and proteins present a different analytical challenge compared to small molecules due to their size 34 
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and physico-chemical properties. They therefore require a different approach for method 35 
development activities. There are various publications which are intended to predict peptide 36 
retention times based primarily on hydrophobicity and sequence. The success of these predictions is 37 
based on an understanding of the role of hydrophobicity based on amino acid side chain differences 38 
as well as the secondary structure of the peptide [3-7]. However, there are currently no publications 39 
available describing a peptide-based approach for the characterisation and identification of columns 40 
with different or similar selectivity for peptide separations to assist in developing methods.  41 
The development of purity methods that separate the active pharmaceutical ingredient from its 42 
impurities and degradation products is quite challenging and the potential presence of isomeric 43 
species via racemisation in particular can be difficult to determine. Due to their identical mass to 44 
charge ratio, isomers cannot be determined directly by mass spectrometry. Thus, screening of 45 
combinations of columns and mobile phases that provide large differences in selectivity is of critical 46 
importance for the development of purity methods for peptide-based drug products.  47 
Chromatographic methods for biomolecules are often designed based on past experience. This lack 48 
of a systematic approach can prove time consuming and a poor use of valuable resources. This is 49 
contrary to small molecule separations where there are various articles on the retention 50 
mechanisms of small molecules using different stationary phases, therefore method development 51 
approaches and stationary phase selection can be made based on rational choice from column 52 
characterisation protocols [8-14].  53 
Column characterisation is a process which uses well defined molecular probes, under controlled 54 
chromatographic conditions, which allows for direct comparison between different stationary 55 
phases, manufacturer and batches of columns. For small molecule work there are many reversed 56 
phase chromatography (RPC) characterisation protocols which have resulted in several databases, 57 
the largest being Snyder’s Hydrophobic Subtraction Model in the PQRI database and the Tanaka and 58 
extended protocols by Euerby et al. in the ACD database which are both freely available on the 59 
internet [9-13]. Lesellier et al. alternatively use supercritical fluid chromatography (SFC) to 60 
characterise reversed phase stationary phases based on linear solvation energy relationships (LSER) 61 
[14]. The different protocols can provide information on the hydrophobicity, steric interactions, 62 
hydrogen bonding capability and ion exchange capacity of a column. It is, however, unclear how 63 
relevant column characterisations based on small molecules are for the selection of columns for 64 
peptides and proteins. This was confirmed by Hodges’s et al. who concluded that there was very 65 
little correlation between the small molecule PQRI database and the retention of a range of 66 
peptides.  The peptides in the study contained a high proportion of glycine residues to prohibit any 67 
“nearest neighbouring effects” in order to gain a greater fundamental understanding of interactions 68 
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between each amino acid and the stationary phase, and to minimise any higher order structure such 69 
as alpha helix and beta sheets [15-16].  Our study extends on Hodge’s initial work to investigate 70 
more biologically active peptides which would have potential interferences from “nearest neighbour 71 
effects”.  72 
This first paper in a series will describe the design of a peptide-based characterisation protocol 73 
known as the Peptide RPC Column Characterisation Protocol which will investigate the factors 74 
contributing to the selectivity of reversed phase separation systems and assist in the development of 75 
rational method development strategies for the separation of peptides using mobile phases selected 76 
to meet industry best practices. This currently includes stationary phases but will also eventually 77 
include mobile phase composition. This will increase the understanding surrounding selectivity of 78 
peptide separations with general mechanisms investigated but also more specifically looking at 79 
separations involving degradation and isomeric species. The characterisation protocol can be 80 
adapted to develop a column characterisation database similar to that available for small molecule 81 
reversed phase chromatography. A database will facilitate the identification of backup columns for 82 
existing methodologies and highlight complementary stationary phase combinations with large 83 
selectivity differences for method development purposes.  84 
 85 
2 Experimental 86 
2.1 Chemicals and Reagents 87 
All water and acetonitrile used were of LC-MS grade and supplied by Sigma Aldrich (Poole, UK). The 88 
compounds used in the system suitability test (SST) and the mobile phase additives (ammonium 89 
formate, formic acid and trifluoroacetic acid) were also supplied by Sigma Aldrich. Dimethylsulfoxide 90 
(DMSO) was supplied by Fisher Scientific (Hemel Hempstead, UK). The peptides, which were 91 
supplied by Apigenex (Prague, Czech Republic), were all dissolved individually in DMSO/H2O (80:20 92 
v/v) to a concentration of 0.25 mg/mL.  Solutions were stored at -20 °C. 93 
 94 
2.2 Chromatographic Conditions 95 
LC separations were performed on a Shimadzu Nexera X2 UHPLC system (Duisberg, Germany) 96 
equipped with two binary pumps (LC-30AD) and proportionating valves, degassers (DGU-20ASR), 97 
autosampler with cooling capabilities (SIL-30AC), Prominence column oven (CTO-20AC), diode array 98 
detector (SPD-M30A) and communication bus module (CBM-20A). A Shimadzu single quadrupole 99 
Mass Spectrometer (LCMS 2020) was used as a secondary detector with positive electrospray 100 
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ionisation. The LC configuration had a dwell volume of 342 µL and system retention volume of 14 µL 101 
[17]. The software used to control the LC system was LabSolutions (Version 5.86).  102 
 103 
2.2.1 Peptide RPC Column Characterisation Protocol Conditions 104 
The test conditions utilised both low and intermediate pH to affect selectivity. The low pH mobile 105 
phases were prepared as follows A1: 0.1% v/v formic acid in water and B1: 0.1% v/v formic acid in 106 
acetonitrile. Formic acid was dispensed using a 1000 µL variable pipette where accuracy was 107 
confirmed at each preparation of mobile phase. The gradient at low pH was as follows: 5-45 %B over 108 
40 minutes, where it was held at 45%B for 2 minutes, before dropping to initial conditions in 0.1 109 
minutes, and re-equilibrated for 12 minutes (equivalent to 10 column volumes). The intermediate 110 
pH mobile phase was prepared as follows A2: 20 mM ammonium formate in water and B2: 20 mM 111 
ammonium formate in acetonitrile/water (80:20 w/w). Solutions were prepared from a 200 mM 112 
stock buffer solution (native pH 6.45). The gradient at intermediate pH was as follows: 5.6-61.9 %B 113 
over 40 minutes, where it was held at 61.9%B for 2 minutes, before dropping back to initial 114 
conditions in 0.1 minutes. The system re-equilibrated for 12 minutes (equivalent to 10 column 115 
volumes). Initial investigations utilised a B solvent consisting of 90% acetonitrile, however, the 116 
resulting solution was initially turbid with the 200 mM ammonium formate which would become 117 
homogeneous upon sufficient mixing. However, in order to increase the ruggedness of the protocol, 118 
the B solvent was changed to 80% acetonitrile and the %B/min change adjusted accordingly to the 119 
percentages described in this paper to maintain selectivity.  120 
Separations were performed at 40 °C and 0.3 mL/min flow rate. A wavelength of 215 nm was used 121 
with background correction at 360 nm, with bandwidths of 8 and 100 nm, respectively. Selected ion 122 
monitoring (SIM) in positive ESI mode was used to track the peaks based on the z=2 charge, which 123 
was the most abundant ion for the majority of the peptides. Isomers were tracked based on m/z and 124 
peak area using different concentration in the same sample. 125 
The programmable autosampler was used to prepare the peptide mixtures within the autosampler, 126 
allowing for minimal waste of sample. These test mixtures contained two reference peptides, which 127 
covered the range in hydrophobicities (i.e. a weakly and strongly retained peptide). Each peptide 128 
mixture contained between 5-7 peptides (see Table 3 for a list of the peptides). Samples were stored 129 
in the autosampler at 10 °C. 130 
So as to investigate whether TFA masked certain interactions, the mobile phases were as follows A3: 131 
0.1% v/v TFA in water and B3: 0.1% v/v TFA in MeCN. TFA was dispensed from 1 mL aliquots. The 132 
same gradient was used as formic acid on the columns described in Section 2.3, whilst all other 133 
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operating parameters were as described above. The procedure was applied to a reduced number of 134 
peptides which were found to be the most discriminating for column characterisation.   135 
 136 
2.2.2 System Suitability Test Conditions 137 
The SST mixture contained water or uracil (dead time marker), benzylamine (changes in silanophilic 138 
activity and negative charge), benzene sulfonic acid (changes in positive charge), benzyl alcohol, 139 
caffeine (changes in hydrogen bonding), phenol (changes in phenolic interactions [18]), toluene, 140 
butyl benzene and pentyl benzene (changes in hydrophobicity). 0.1% formic acid v/v in water was 141 
assigned to Line A1 and 0.1% formic acid v/v in acetonitrile was assigned to Line B1. A gradient of 142 
5%B at 0 minutes increased to 100% over 20 minutes, where it was held for 2 minutes before 143 
dropping to initial conditions in 0.1 minute. The column was re-equilibrated for 12 minutes.  144 
Separations were performed at 40 °C and 0.3 mL/min flow rate. Wavelengths of 215 and 254 nm 145 
were used with background correction at 360 nm, and bandwidths of 8 and 100 nm, respectively.  146 
 147 
2.3 Columns 148 
All columns assessed were new as supplied by the manufacturer and were standardised in the 150 x 149 
2.1 mm column format, with particle size (dp) varying between 1.7 to 3 µm (Table 1). The peak apex 150 
of a water injection was used as the dead time marker for each column [17]. All stationary phases 151 
were assessed using Tanaka and extended characterisation protocols which are well described in 152 
literature [9,19] and can be accessed via the free ACD website [11]. The integrity of the stationary 153 
phases was ensured before and after usage by an SST (Section 2.2.2) which assessed the column for 154 
changes in hydrophobicity, hydrogen bonding, positive charge and negative charge (silanol activity). 155 
The selection of the stationary phases was based on prior knowledge of the columns and it was 156 
presumed would offer a wide range in selectivity to be representative of a larger collection of 157 
stationary phases, ideal for a characterisation database. Some columns possessed a large positive 158 
charged surface whilst others had a high degree of residual silanol groups in order to characterise a 159 
wide array of column functionalities. Some of the columns chosen would not normally have been  160 
selected when developing state of the art peptide methods but were essential to establish a 161 
database. 162 
An array of C18 phases were selected which differed by base silica (i.e. Acquity BEH C18, Acquity CSH 163 
C18 and Acquity HSS C18). In addition to selecting columns which could offer different selectivity, it 164 
is of interest to investigate the subtleties between similar phases to be able to identify back up 165 
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columns. The ligand density was also evaluated which could impact on selectivity by changing the 166 
architecture of the particle and accessibility to the silica surface (i.e. Acquity HSS C18 SB and Acquity 167 
HSS T3). 168 
A series of alkyl lengths were also evaluated to assess the effect of varying hydrophobicity where 169 
observed selectivity differences can possibly be explained as a function of chain length differences 170 
(i.e. Acquity BEH C4, Acquity BEH C8 and Acquity BEH C18).  171 
A commonly used range of columns include polar embedded group (PEG) and phenyl phases, which 172 
can offer alternative selectivity. A carbamate ligand (Acquity BEH Shield RP18) and an amide ligand 173 
(Polar Amide C18) were selected to represent two styles of PEG functionalities and synthetic routes, 174 
where the amide phase is prepared via a two-step synthetic route which generates positive 175 
character to the phase due to residual amino groups, whilst the carbamate is a one-step synthetic 176 
route thus can be considered neutral. The phenyl phases (i.e. Acquity CSH Fluoro Phenyl, Acquity 177 
CSH Phenyl Hexyl, Ascentis Express Biphenyl and Fortis Diphenyl) vary by alkyl linker (i.e. C3-C6), 178 
fluoro-substitutions and the number of aromatic rings, which all impact on the available interactions 179 
with probes.  180 
The final phase selected to develop the characterisation protocol was the Acclaim Mixed Mode WCX, 181 
which is a weak cation exchange phase based on a carboxylic acid moiety. This phase can offer 182 
hydrogen bonding interactions at low pH with the protonated carboxylic acid moiety and substantial 183 
electrostatic interactions at intermediate pH via the negatively charged dissociated carboxylic acid.  184 
Both types of interactions might provide selectivity differences for polar and charged peptide 185 
species. 186 
 187 
2.4 Software and Calculations 188 
Principal Component Analysis (PCA) was performed using SIMCA (Version 14.1, Umetrics, Umeå, 189 
Sweden) and Origin (Version OriginPro 2016, OriginLab, Northampton, MA, USA). The variables 190 
within the PCA were all autoscaled, in order to give each variable the same importance. The net 191 
charges of the peptide probes were calculated at both pH 2.5 and 6.45 using General Protein/Mass 192 
Analysis for Windows (GPMAW) software (Version 9.51, Lighthouse Data, Odense, Denmark). 193 
 194 
3 Results and Discussion 195 
3.1 Rationale for Design of Peptide  196 
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Bovine GLP-2, which is similar to Human GLP-2, was selected as the base sequence to probe the 197 
stationary phases (Table 2). It is relevant to the biopharma industry, has a typical chain length and 198 
possesses typical degradation sites. Additionally, Bovine GLP-2 is an attractive probe as it does not 199 
contain cysteine which is likely to limit the stability of peptides due to sulfide bridge formation or 200 
shuffling [20].  201 
The peptide chain contains 33 amino acids, and has the propensity to form secondary structures 202 
such as alpha helix or beta sheets. The length of the peptides was reduced to 15 and 18 amino acids 203 
to reduce the probability for a secondary structure in an aqueous environment [21]. This length is 204 
similar to the length typically obtained by proteolytic digests of proteins [16]. A lack of secondary 205 
structures was confirmed using circular dichroism in organic / aqueous conditions and temperature 206 
corresponding to the chromatographic conditions where the characteristic absorbances were absent 207 
for any higher order structure [22].  208 
Bovine GLP-2 can be viewed as having a more hydrophilic segment (amino acids 1-15, in Table 2) and 209 
a more hydrophobic segment (16-33). The use of the two base sequence segments instead of the 210 
single peptide would minimise the probability of secondary structures and allow for a selection of 211 
peptide probes to be synthesised which potentially could be explained in terms of retention and 212 
selectivity.  In total, 26 rationally designed peptide probes were synthesised to characterise the 213 
peptide separation system. The altered position in the peptide sequence and physico-chemical 214 
properties (i.e. logP, pI and net charge) can be seen in Table 3. 215 
The peptide chain contained several sites for common degradation, which include racemisation, 216 
isomerisation, oxidation and deamidation. Racemisation can occur at the chiral centre of the α 217 
carbon forming the D-isomer, where the rate of racemisation can depend on reaction parameters 218 
such as pH, temperature and solvents. This is particularly prevalent for serine and histidine which are 219 
known to be susceptible to racemisation during the synthetic process [23-24]. The sequence 220 
provided four racemisation sites for serine or histidine (Peptide Numbers 2, 6, 7 and 14). Aspartic 221 
acid is also known to undergo racemisation in addition to isomerisation to the isoaspartate, thus a 222 
further eleven analogues were synthesised to probe the separation of the racemic and isomeric 223 
degradants (Peptide Numbers 3, 4, 5, 9, 10, 11, 12, 16, 17, 18 and 19). 224 
Oxidation can be explored via the methionine residue at position 10 in the chain (Peptide Number 225 
8). It can readily oxidise during the synthetic process or during storage into two diastereoisomeric 226 
sulfoxide species by means of the lone pair of electrons on the sulfur in a 1:1 ratio.  227 
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The loss of an amide functionality from a peptide is known as deamidation. This is observed for the 228 
amino acids glutamine and in particular asparagine [25-26], especially when adjacent to an amino 229 
acid such as glycine, serine or threonine. A cyclic succinimide intermediate forms between the 230 
peptide bond and the asparagine side chain, which can ring open to form both the D- and the L- 231 
forms of aspartate or isoaspartate via hydrolysis. A series of deamidation, racemisation and 232 
isomerisation were explored using Peptide Numbers 9-12. 233 
The more hydrophobic peptide chain was typically used to investigate specific modifications at 234 
certain points of the peptide chain, with the intention of gaining a greater understanding of the 235 
peptide-column interactions by examining a series of modifications (Peptide Numbers 13,15,20-26).  236 
Steric interactions are particularly subtle, but are still an important modification to investigate. 237 
Racemisation can be seen as a form of steric interaction. Other steric interactions probed include 238 
substituting leucine (Peptide Number 13) for valine and isoleucine (Peptide Number 20 and 21), 239 
which differs by a methylene group and branching and by switching the order of two amino acids 240 
(Peptide Number 15).  241 
Changing the charge of the peptide can have a substantial effect on its retentivity and can be 242 
affected by different stationary phase, mobile phase composition and pH. It is possible to investigate 243 
the effect of a small change in polarity and basicity with the same charge by modifying arginine (side 244 
chain pKa 12.48, Peptide Number 13) in position 20 with a lysine (side chain pKa 10.35, Peptide 245 
Number 25). The effect of changing from a neutral amino acid to a positive species can also be 246 
investigated with the addition of lysine in place of leucine in position 26 in Bovine GLP-2 (16-33) 247 
(Peptide Number 26). An increase in negative charge was probed by the addition of an aspartic acid 248 
in various positions along the chain (Peptide Numbers 4, 5, 9, 10, 11, 12, 16, 17, 18 and 19). 249 
Other mechanisms of interest were aromatic and phenolic effects, which were investigated by 250 
exchanging leucine for phenylalanine, tryptophan or tyrosine (Peptide Numbers 22, 23 and 24, 251 
respectively). Small molecules are highly influenced by aromatic and phenolic effects, however, it is 252 
uncertain how the change of a single amino acid in a peptide will impact on selectivity, since this is a 253 
relatively subtle modification of the peptide compared to a small molecule. Mant et al. did observe 254 
selectivity differences on a range of peptides similar in size which differed by one amino acid [16,27], 255 
however, their peptides had several glycine residues throughout the sequence to prevent any 256 
secondary structure.  This might not be the case for biologically active peptides which typically are 257 
more heterogenic.  258 
 259 
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3.2 Rationale for Selection of Buffers 260 
Peptide analysis at low pH typically includes either of the following mobile phase additives: 261 
phosphate salts, trifluoroacetic acid (TFA), ammonium formate, ammonium acetate or formic acid 262 
[28-29]. Phosphate salts are frequently used within the biopharmaceutical industry for peptide 263 
separations as they often provide a favourable selectivity and peak shape, however, they were not 264 
favoured in the protocol due to their lack of volatility which prohibits peak identification using MS 265 
detection. TFA is a frequently used additive as it is a good compromise, i.e. it gives both acceptable 266 
chromatographic and MS performance. It was not selected for the protocol as it was shown to mask 267 
electrostatic and more subtle polar interactions between the peptides and the stationary phases 268 
hence reducing the discriminating power of the column characterisation protocol (see section 3.4). 269 
As it can also irreparably modify the stationary phase surface, it would be impractical for the 270 
protocol, in that once exposed to TFA the column could not be used with other additives in the 271 
characterisation protocol [30]. The intention of this present study was to develop a simple and 272 
robust column characterisation protocol, by differentiating the subtle interactions of peptides with 273 
the stationary phase surface and not to develop optimum LC methods. TFA and other interesting or 274 
commonly used mobile phases will however be characterised in a following study which could 275 
potentially aid the chromatographer in the selection of the most appropriate mobile phases for 276 
method development. 277 
The primary rationale for selecting formic acid as the mobile phase additive for the column 278 
characterisation protocol was its lack of masking subtle interactions (compared to TFA) and hence 279 
enhance the discriminating power of the protocol. Additional benefits included its ease of tracking 280 
peaks using MS detection, volatility and lack of signal suppression in positive electrospray ionisation. 281 
Formic acid would not normally be used for LC-UV due to the poor peak shapes that it typically 282 
generates but is advantageous in that it permits the user to understand the purer interactions of the 283 
stationary phase.   284 
Historically, peptide analysis was performed at low pH in order to minimise the interaction of 285 
peptides with deprotonated residual silanols at intermediate pH which can cause detrimental band 286 
spreading and excessive tailing for ionised species. However, intermediate pH should still be 287 
considered due to the alternative selectivity which it confers by changing the physico-chemical 288 
properties of both the stationary phase and peptides.  289 
Intermediate pH can be established using ammonium formate at its native pH (6.45). Although there 290 
is little buffering capacity at this pH it is LC-MS compatible. An alternative to the formate salt could 291 
be ammonium acetate, however, there is various anecdotal evidence which suggested that the 292 
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acetate salt produced significant adducts in the MS and ion suppression. Both salts are known to be 293 
hygroscopic, which can be problematic for consistent results. This often manifests as clumping in the 294 
salt container but is frequently ignored despite its effect on buffer concentration. A sodium chloride 295 
salt chamber was set up at 20 °C to produce a relative humidity (RH) of 75.47% ±0.14 [31]. Over 6 296 
hours the ammonium acetate had increased in mass by 32.9% and reduced to a liquid, whereas the 297 
ammonium formate had a mass increase of 24.8% and was partially crystalline. A less exacerbated 298 
scenario was set up at ambient humidity using a magnesium chloride salt chamber (RH 33.07% 299 
±0.18), which saw a mass increase of 7.9% for ammonium acetate and 3.3% for ammonium formate 300 
over 6 hours. A comparison of ammonium acetate and ammonium formate highlighted no 301 
difference in the degree of cluster formation in the MS, although there was some improved 302 
sensitivity achieved with the formate salt on a selection of peptides (up to 2x greater), thus 303 
ammonium formate was used to characterise the stationary phases at intermediate pH.  304 
 305 
3.3 Normalisation and Definition of Selectivity 306 
Two reference peptides were included in each peptide mixture in order to monitor any retention 307 
time drift and to normalise retention time. The normalisation can also minimise variation related to 308 
instrumentation, solvents, analyst and remove any contribution from the dwell volume of the 309 
system (Vd) and column volume (Vm) in order to gain greater robustness for the overall procedure 310 
(Eq. 1). Normalisation of the peptide’s retention was feasible due to the fact that the peptides were 311 
focused on the top of the column [32-35].  312 
𝑡𝑔
∗ =  
𝑡𝑔− 𝑡𝑔 𝑅𝑒𝑓1
𝑡𝑔 𝑅𝑒𝑓2−𝑡𝑔 𝑅𝑒𝑓1
 (1) 313 
Where tg is the retention in gradient elution, tg Ref1 is the retention in gradient elution of the first 314 
eluting isomer of [Met(O)10]-Bovine GLP-2 (1-15) (Peptide Number 8a) and tg Ref2 is the retention in 315 
gradient elution of [Ile26,Leu27]-Bovine GLP-2 (16-33) (Peptide Number 15) (Fig. 1). These peptides 316 
are the first and typically last eluting compounds, thus tg* values generated were between 0 and 1.  317 
Selectivity in gradient chromatography (α*) has been defined in various publications [33-34] where 318 
gradient chromatography presents a more complex situation than for isocratic chromatography in 319 
that changing eluent composition, dwell volume, column dead volume and gradient shape can all 320 
influence the selectivity. A variety of α* measures were evaluated using the peptides with the most 321 
robust and intuitive defined equation in Eq. 2, where tg is the retention time in gradient elution and 322 
tm and td are column dead time and dwell time, respectively.  323 
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∝∗=  
𝑡𝑔2
′
𝑡𝑔1
′   (2) 324 
𝑡𝑔
′ =  𝑡𝑔 − 𝑡𝑚 − 𝑡𝑑 (3) 325 
However, the result produced by α* was heavily dependent on the point of elution in the gradient, 326 
despite visually having a similar degree of separation. The peptides of interest would produce a 327 
reduced α* value if retained for longer on the gradient in comparison to a less retained pair of similar 328 
separating power, thus suggesting selectivity differences. Therefore, an alternative measure was 329 
required to define selectivity.  330 
A better representation of selectivity was delta (Δtg*, Eq. 4), which was the difference in normalised 331 
retention time between two peaks. Delta values were preferred over α*, as it rectified the 332 
discrepancy to provide identical selectivity, regardless of the point of elution in the gradient. This 333 
measure allowed direct comparison between stationary phases and mobile phases irrespective of 334 
the point of elution, thus giving a purer representation of the selectivity differences. In addition, Δtg* 335 
also compensates for differences in dwell time (td). 336 
∆𝑡𝑔
∗ =  𝑡𝑔2
∗ − 𝑡𝑔1
∗  (4) 337 
In total, 33 delta values per mobile phase were identified based on various properties, including 338 
racemisation, steric interactions, increases in positive charge or negative charge, changes due to 339 
oxidation and change in hydrophobicity / alkyl and changes in hydrogen bonding or aromatic 340 
character (Table 4). The average Δtg (expressed in minutes) and average Δtg* were recorded in Table 341 
4 for the formic acid, TFA and ammonium formate gradient conditions, to allow for better 342 
judgement of what is a large or small difference in selectivity. The sign in front of the Δtg* result is 343 
indicative of the elution order for the separation. The largest average difference was observed using 344 
formic acid between [Leu26]- and [Lys26]-Bovine GLP-2 (Peptide Number 13 and 26, respectively), 345 
which could be expected due to the changes in charge. The smallest average differences (i.e. Δtg* 346 
values close to zero) were typically racemic in nature, which highlights the difficulty in separating 347 
these closely related species. The difference in responses for the position of the racemisation also 348 
accentuates the issue of analysing racemates, where [L-Ser5] → [D-Ser5] and [L-Ser7] → [D-Ser7]-349 
Bovine GLP-2 (1-15) differ at position 5 and 7 respectively in the residue chain, but produced some 350 
signficant differences in  Δtg* for both formic acid and ammonium formate (Peptide Number 1, 6 and 351 
7).  352 
 353 
3.4 Principal Component Analysis  354 
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A significant amount of information was produced in the data matrix thus the chemometric tool 355 
Principal Component Analysis (PCA) was used to visualise trends within the data, by reducing the 356 
number of variables (i.e. delta values) to two principal components [9,36]. The delta values were all 357 
coded based on the interaction of interest (Table 4). The loading plot (Fig. 2) illustrates how the 358 
different delta values contribute to the two principal components. Delta values located close to each 359 
other have similar importance for the differentiation of objects (i.e. columns). 56% of the variation 360 
between columns were described using two principal components. The use of a third principal 361 
component increased the variation described by only 11% and did not provide any additional 362 
information, thus only two principal components were used. The corresponding score plot (Fig. 3) 363 
shows how similar or different columns are to each other. Columns located close to each other are 364 
more similar. The columns in Fig. 3 were all colour coded based on prior knowledge of stationary 365 
phase properties to gain an understanding of potential groupings. The green circles are phases with 366 
neutral character i.e. high hydrophobicity and low degree of silanophilic interactions due to greater 367 
ligand density and end-capping. The blue squares are phases with negative character, such as those 368 
with low ligand coverage or absence of end-capping and thus a high degree of silanophilic 369 
interactions.  The inverted red triangles are phases with positive character i.e. presence of a 370 
positively charged group in addition to the hydrophobic ligand [11].  371 
The Acclaim Mixed Mode WCX was excluded from the PCA despite adequate peak shape and 372 
performance under low pH conditions for all the peptides, as the carboxylic acid moiety on the 373 
mixed mode phase was ionised at pH 6.45, which resulted in poor retention of Peptides 1-12. These 374 
peptides can be considered more hydrophilic and possess a charge between -3.7 and -4.7 at the 375 
intermediate pH. The affected peptides eluted in the void under those chromatographic conditions, 376 
which would heavily skew the score and loading plots, thus the decision was made to exclude the 377 
Acclaim Mixed Mode WCX for the purpose of comparison. A biplot was created solely from formic 378 
acid data on all 14 columns, where the Acclaim Mixed Mode WCX was grouped with the negative 379 
character stationary phases and located as far from the origin as the Acquity CSH Fluoro Phenyl and 380 
consequently should display very different selectivity for appropriate peptides i.e. peptides with 381 
limited negative net charge.  382 
The possibility of reducing the number of delta values required for the Peptide RPC Column 383 
Characterisation protocol was evaluated by performing an iterative study which removed any 384 
variable near the origin in the loading plot (i.e. considered an insignificant variable), or removal of 385 
variables with similar meanings whilst ensuring the integrity of the score plot was maintained (i.e. a 386 
maintained relative location of columns). Following a step-wise process of elimination, the number 387 
of variables within the Peptide RPC Column Characterisation Protocol was reduced from 66 to 11, 388 
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whilst still covering an array of important interactions. Six of the measurements were determined in 389 
ammonium formate, whilst the remaining five were measured in formic acid, using a total of three 390 
test mixtures (summarised in Table 5). The delta value to be measured were calculated from the 391 
same test mixture to increase the robustness of the procedure.  392 
A biplot of the final Peptide RPC Column Characterisation Protocol peptides (i.e. a combined score 393 
and loading plot, Fig. 4) highlighted the influence an observation has on the position of the 394 
stationary phase. Regions of electrostatic interactions can be deciphered, where the phases with 395 
negative character in the upper quadrants (e.g. Acquity HSS C18-SB and Acquity BEH C4) are 396 
dominated by the positive charge delta values, and the phases with positive character in the lower 397 
quadrants (e.g. Polaris Amide C18 and Acquity CSH Phenyl Hexyl) are correlated with the negative 398 
charge delta values. There is also an intermediate region of low electrostatic interactions for the 399 
stationary phases with a neutral character which have low silanophilic activity due to high ligand 400 
density and extensive end-capping.  401 
In order to investigate the hypothesis that TFA masks certain interactions between the column and 402 
the peptide, a study was conducted where 0.1% v/v formic acid was substituted with 0.1% v/v TFA in 403 
both the aqueous and organic phase on the reduced number of delta values. 13 columns were 404 
tested using a simplified and more robust version of the protocol described in reference [37] which 405 
used 8 of the 11 probes to increase the reliability of the methodology. Distinct groups can be 406 
observed in the formic acid biplot plot Fig. 5(A) with 87% of the variability described, where the 407 
position of the columns can be rationalised based on what is known about the column characters. 408 
With TFA, it is no longer possible to see these distinct groupings, and only 68% of the variability is 409 
described, which suggests a less clear structure for that dataset (Fig. 5(B)). This would appear to 410 
confirm the hypothesis that TFA will mask peptide-column interactions and thus columns become 411 
more similar. Stationary phases such as the Acquity HSS C18-SB with no end-capping and low surface 412 
coverage appear similar to columns with end-capping and positive charge like Acquity CSH Fluoro 413 
Phenyl and Polaris Amide C18 which are very different. As such, to describe the interactions of the 414 
columns, it is important to assess each column using formic acid, rather than TFA. A further 415 
evaluation of TFA as an additive will be described in a subsequent article where mobile phases are 416 
characterised. 417 
 418 
3.5 Peak Capacity 419 
Large selectivity differences on their own are not sufficient for generating a good chromatographic 420 
method. Chromatographic efficiency is also required, which is measured by peak capacity in gradient 421 
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elution. Peak capacity is defined as the total number of peaks which can be resolved (Rs = 1) within a 422 
chromatogram, and is conventionally measured by dividing the gradient time by the average peak 423 
width. However, this measurement often over estimates the performance of the column, thus the 424 
sample peak capacity (PC**) approach was used (Eq. 5) to determine the peak capacity for the 425 
fraction of the gradient used to separate all the compounds of interest [23].  426 
𝑃𝐶∗∗ =  
𝑡𝑔 𝑚𝑎𝑥− 𝑡𝑔 𝑚𝑖𝑛
𝑊𝑎𝑣𝑒
+ 1 (5) 427 
Where tg min and tg max are the retention time of the first and last eluting peptide. wave is the average 428 
width at base for all peaks that are separated except the diastereoisomeric oxidised methionine 429 
probe which is typically unresolved on most of the stationary phases.   430 
The PC** was measured for both the formic acid, ammonium formate and TFA gradient conditions on 431 
the reduced number of delta values. The greater performance, as shown by increased PC** values, 432 
was typically achieved using intermediate pH (Table 6 and Fig. 6). Formic acid characteristically 433 
provides poorer performance, whilst TFA usually produced good values of peak capacity. Despite 434 
poorer performance, the formic acid was still within 28% on average of the peak performance 435 
produced in TFA and 41% in ammonium formate.  436 
Poor peak shape at low pH is often attributed to silanophilic interactions, however, with the increase 437 
in modern silicas which do not possess a significant degree of acidic silanols, this cannot be the cause 438 
of exaggerated peak shapes for basic species. McCalley et al. hypothesised that poor peak shape can 439 
often be ascribed to overloading for basic species due to mutual repulsion effects between adsorbed 440 
ions of the same charge [28,38-39]. This effect was increased further when low ionic strength mobile 441 
phases are used. Further research by McCalley, which used positively charged peptide probes also 442 
supported this theory where he compared the responses of four multiply positively charged peptides 443 
in phosphate buffer, formic acid and TFA. The phosphate buffer gave significantly better peak shape 444 
and chromatographic performance compared to the formic acid due to a significantly higher ion 445 
strength which reduces mutual repulsion. TFA also gave improved peak shape compared to formic 446 
acid, however, in this case it was also accredited to the ion pairing effects of TFA which could reduce 447 
overloading by partially neutralising the net charge of the peptides and thereby removing the 448 
repulsion effects [28].   449 
Although formic acid can result in poor peak shape, this was not the case for the Acquity CSH range 450 
of stationary phases which were specifically designed to provide an improved peak shape for basic 451 
species due to the presence of a small permanent positive character on the surface of the phase 452 
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[40]. The Polaris Amide C18, which also possessed a positive character, additionally provided good 453 
chromatographic performance in formic acid.   454 
 455 
3.6 Assessment of Peptide – Column Interactions  456 
3.6.1 Hydrophobic interactions 457 
Hydrophobic interaction, which is the primary retention mechanism in reversed phase 458 
chromatography, could be evaluated by investigating the effect of probes possessing differing 459 
hydrophobicity (i.e. changing leucine to valine) and by changing the hydrophobicity of the stationary 460 
phase (i.e. different alkyl length).  461 
Mant et al. deduced the order of hydrophobicity for amino acids when there are no “nearest 462 
neighbour” effects [27]. A purely hydrophobic interaction without “nearest neighbour” effects would 463 
therefore suggest that the elution order in this study should be Val<Tyr<Ile<Leu<Phe<Trp, i.e. 464 
Peptide 20<24<21<13<22<23. This was, however, not the case as seen in Fig. 7. One explanation can 465 
be that the peptides in the current study lack a secondary structure in the mobile phase as shown by 466 
CD but form a secondary structure in the hydrophobic acetonitrile layer on the stationary phase 467 
resulting in another elution order.   468 
[Leu26]- and [Val26]-Bovine GLP-2 (16-33) (Peptides 13 and 20) differ by just one methyl group, 469 
which represents a subtle change in the peptide’s overall hydrophobicity, however, when compared 470 
on a range of C18 phases (Acquity BEHs, HSSs and CSHs) there were substantial selectivity 471 
differences between the two probes (Fig. 7 (A), (D) and (G)). This is in agreement with Mant et al. 472 
who witnessed greater retention for a peptide modified with a leucine compared to one modified 473 
with a valine [27]. [Ile26,Ile27]- and [Leu26,Ile27]-Bovine GLP-2 (16-33) (Peptides 21 and 13, 474 
respectively) only differ by the position of a methylene group on the side chain, however, they have 475 
substantial selectivity differences on the C18 phases during gradient elution. Literature suggests it is 476 
reasonable to expect retention differences between these two peptides, as the β-branched chain on 477 
the isoleucine is closer to the peptide backbone, thus less able to interact with the stationary phase 478 
[27]. This is again in agreement with the previous study, where the peptide modified with leucine 479 
had greater retention than the peptide modified with isoleucine.  480 
[Ile26,Leu27]- possesses the same overall hydrophobicity as [Leu26,Ile27]-Bovine GLP-2 (16-33) 481 
(Peptides 15 and 13, respectively), but have substantial selectivity differences on the C18 phases 482 
during gradient elution (Fig. 7 and 8), which suggests an alternative mechanism. One possible 483 
explanation could be that the change in position of the methyl group changes the shape of the 484 
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peptide in the hydrophobic acetonitrile layer on the stationary phase and that results in differences 485 
in the interactions which can take place [41-43].  486 
The more hydrophobic molecules [Phe26]-, [Trp26]- and [Tyr26]- (Peptides 22, 23 and 24) were then 487 
compared against [Leu26]-Bovine GLP-2 (16-33) (Peptide 13). Based on retention data obtained by 488 
Mant et al., although they possess bulkier, aromatic side chains, a hydrophobic retention mechanism 489 
should preferentially retain [Phe26]- and [Trp26]- over [Leu26]-Bovine GLP-2 (16-33) (Fig. 7). [Tyr26]-490 
Bovine GLP-2 (16-33) should be the least retained of the four peptides described. However, on all of 491 
the C18 phases, [Phe26]-, [Trp26]- and [Tyr26]- eluted earlier, which confirms that a hydrophobic 492 
retention mechanism must be acting in combination with an alternative mechanism.  493 
The same phenomenon was experienced on the Acquity BEH alkyl range of stationary phases, where 494 
a lack of pure hydrophobic mechanism was observed (Fig. 7 (A), (B) and (C)). There was a subtle 495 
change in elution order for the Acquity BEH C8 and C4, however, where [Ile26]- and [Phe26]- 496 
(Peptides 21 and 22) switched in elution order. One possible explanation could be that the aromatic 497 
groups change the shape of the peptide in the adsorbed acetonitrile layer and thereby expose other 498 
groups which can participate in polar / electrostatic interactions [41-43].  499 
There are subtle selectivity differences between the stationary phases, however, to a large extent, 500 
the type and length of the ligand (C4-C18) does not appear to be critical for the separation of these 501 
probes.  502 
 503 
3.6.2 Electrostatic Interactions 504 
The addition of negative charge was evaluated using peptides [L-Asp11]- and [Asn11]-Bovine GLP-2 505 
(1-15) (Peptides 9 and 1 respectively). Their retentions were compared on stationary phases with 506 
negative and positive character (Fig. 9) where in formic acid, both sets of columns eluted the 507 
asparagine peptide before the aspartic acid variant. In ammonium formate, however, the elution 508 
order was reversed, and the aspartic acid eluted first. Under intermediate pH conditions (pH 6.45) 509 
the aspartic acid peptide has a net charge of -4.7 whilst the asparagine peptide has a net charge of -510 
3.7, and as such, [L-Asp11]- would be expected to elute last on the phases with positive character 511 
due to enhanced electrostatic interactions. However, as the more acidic species [L-Asp11]- eluted 512 
first it suggests that despite having a greater negative charge than [Asn11]-, it is the position of the 513 
charge and accessibility in the adsorbed peptides secondary structure that is important rather than 514 
the overall net charge of the peptide hence the more charged / hydrophilic [L-Asp11]- elutes first.   515 
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The addition of positive charge was then investigated using the probes [Lys26]- and [Leu26]-Bovine 516 
GLP-2 (16-33) (Peptides 26 and 13, respectively). [Lys26]- eluted first on all stationary phases and 517 
mobile phases, however, there was increased retention under ammonium formate conditions due to 518 
increased electrostatic interactions. The difference is most pronounced for the Acclaim Mixed Mode 519 
WCX which contains a carboxylic acid functionality. At pH 6.45, the carboxylic acid is deprotonated 520 
and thus the positively charged [Lys26]- becomes strongly retained. Due to repulsion, columns with 521 
a positive character (the CSH series and the Polaris Amide C18 columns) elute [Lys26]- earlier at low 522 
pH than columns with a negative character (i.e. more accessible silanol groups).  523 
These interactions are confirmed by the position of the stationary phases and the delta values within 524 
the biplot (Fig. 4).  525 
 526 
3.6.3 Hydrogen Bonding Interactions 527 
Prior knowledge of the stationary phases suggested those phases which are likely to form hydrogen 528 
bonding interactions are the Polaris Amide C18 via the amide functionality, the Acquity BEH Shield 529 
RP-18 via the embedded carbamate moiety, the Acquity BEH C4 and Acquity HSS C18-SB phases via 530 
the short alkyl ligand and low ligand surface coverage respectively which both promote greater 531 
accessibility to the non end-capped silanol groups on the silica surface and the Acclaim Mixed Mode 532 
WCX via the carboxylic acid moiety.  The Acquity BEH C18 was used as a reference since it is based 533 
on hybrid silica, is end-capped and thus should have minimal potential to form hydrogen bonds. The 534 
peptides [Phe26]- and [Tyr26]-Bovine GLP-2 (16-33) (Peptides 22 and 24) were assessed for 535 
hydrogen bonding interactions with the stationary phases as they only differ due to the presence of 536 
the hydroxyl group on the tyrosine. The phenylalanine derivative eluted last on all of the stationary 537 
phases and mobile phases although with greater retentivity in ammonium formate for the tyrosine 538 
variant (data not shown). The trend seems to suggest that polarity is more dominant than hydrogen 539 
bonding capabilities. The extra retentivity in ammonium formate of the tyrosine peptide could 540 
indicate that the stationary phase is becoming more polar. The lack of hydrogen bonding could be 541 
due to the position of the amino acid change in the peptide residue. It is possible hydrogen bond 542 
interactions could be more pronounced if tyrosine was located closer to the terminal amino acids.  543 
There are large selectivity differences observed between the two peptides considering only a 16 Da 544 
difference in their ~2300 Da structures, which indicates the addition of the hydroxyl group has 545 
caused some significant changes in the interactions within the chromatographic system.  546 
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The position of the Acquity BEH Shield RP-18 at the origin in the score plot is highly suggestive that 547 
the carbamate group masks any underlying silanol groups and the carbamate is not involved in any 548 
pronounced hydrogen bonding interactions with [Tyr26]-Bovine-GLP-2 (16-33). 549 
 550 
3.6.4 Aromatic Interactions 551 
Phenyl containing phases (Acquity CSH Phenyl Hexyl, Fortis Diphenyl and Ascentis Biphenyl) and the 552 
pentafluorophenyl phase (Acquity CSH Fluoro Phenyl) were compared against the Acquity BEH C18 553 
and CSH C18 to assess for potential aromatic interactions. The probes used were [Leu26]-, [Phe26]-, 554 
[Trp26]- and [Tyr26]-Bovine GLP-2 (16-33) (Peptides 13, 22, 23 and 24, respectively).  555 
The CSH phases all possessed the same elution order in both formic acid and ammonium formate, 556 
highlighting minimal aromatic retention which suggests the stationary phase ligand becomes less 557 
important for these separations (Fig. 10).  558 
The diphenyl and biphenyl phases on the other hand were able to resolve the aromatic species and 559 
also had different elution orders compared to the CSH phases. [Phe26]- elutes after [Leu26]- and 560 
there is a significantly larger retention of [Phe26]- at mid pH suggesting that this is due to 561 
electrostatic interaction and not due to π-π interactions. The diphenyl and biphenyl phases suggest a 562 
more negative character due to accessible silanol groups whereas the CSH phases have a more 563 
positive character due to positively charged groups in the stationary phase, as indicated within the 564 
PCA (Fig. 4 biplot).  565 
There is the potential that the acetonitrile within the mobile phase could reduce any subtle aromatic 566 
interactions of the peptides with the stationary phase due to competing π-π interactions. The 567 
elution order based on hydrophobicity alone using Hodges’s work would suggest [Tyr26]- elute first, 568 
then [Leu26]-, [Phe26]- and then finally [Trp26]-Bovine GLP-2 (16-33) [27]. However, this was not the 569 
case here where [Trp26]- typically eluted before [Phe26] and [Leu26]-Bovine GLP-2 (16-33). This is 570 
highly suggestive that an alternative retention mechanism must be introduced, such as the 571 
formation of a second order structure of the peptide in the stationary phase exposing certain 572 
functional groups and hiding others. 573 
 574 
3.6.5 Interactions Related to Degradation of Peptides 575 
Purity methods developed for biopharmaceutical peptides should be able to separate degradation 576 
products.  Consequently, an important aspect of the protocol was to evaluate selectivity for common 577 
degradants and racemisation products.  Racemisation and isomeric products are typically 578 
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challenging to separate since these peptides are diastereoisomers with very similar physiochemical 579 
properties.  An investigation of the retention order of D- and L-forms of racemates indicate that the 580 
retention order is often the same at both low and mid pH.  This was the case for 78% of the 117 581 
combinations of delta values and columns in the current study.  A comparison of which pH typically 582 
generates a higher delta value for racemates did not show any trend.  In 54% of the cases mid pH 583 
gave a larger delta value. A similar result was obtained for Asp / isoAsp isomeric delta values, where 584 
73% of the 26 combinations often gave the same elution order in both low and mid pH. However, 585 
there was a trend where low pH gave the large delta value (85% of the combinations).   586 
The biplot (Fig. 4) was used to identify phases which were deemed chromatographically similar and 587 
dissimilar in order to assess their ability to separate racemates. The Acquity CSH Phenyl Hexyl and 588 
Acquity HSS C18-SB were selected as phases with large differences in selectivity for the separation of 589 
[D-Ser16]- and [L-Ser16]-Bovine GLP-2 (16-33) (Peptide Numbers 14 and 13, respectively), whilst the 590 
Acquity HSS T3 and Acquity BEH C18 were compared as phases which provide similar selectivity, i.e. 591 
these phases are located at the extremes and close to the origin when projected on to a line through 592 
the origin and (14,13) in the bi-plot (Fig. 4).  593 
The diverse columns with formic acid (Fig. 11 (A) and (B)) exhibit a difference in the degree of 594 
resolution, where there is coelution but a switch in elution order on the Acquity HSS C18-SB and 595 
resolution achieved on the Acquity CSH Phenyl Hexyl. By switching to ammonium formate (Fig. 11 (E) 596 
and (F)), baseline resolution was achievable on the Acquity CSH Phenyl Hexyl, whilst the Acquity HSS 597 
C18-SB has switched elution order. For difficult separations such as resolving racemic species, it is 598 
essential to have large peak capacity which is typical for mobile phases such as ammonium formate, 599 
whereas solvents which have low ionic strength, such as formic acid, typically failed to resolve the 600 
two species due to poor peak shape. For an explanation of the poor peak shape, see Section 3.5. 601 
In Fig. 11 (C), (D), (G) and (H), the Acquity HSS T3 and Acquity BEH C18 all produced similar looking 602 
chromatograms irrespective of stationary or mobile phase, with similar selectivity and normalised 603 
retention times. 604 
This comparison has provided an early indication that this protocol could show differentiation 605 
between the phases, even for challenging separations such as resolving racemic species. The 606 
example above was selected using (14,13). In order to select columns from the biplot (Fig. 4) likely 607 
to give large differences in selectivity for any racemates the selection would have been Acquity BEH 608 
C8, Acquity HSS C18-SB, Acquity CSH Fluoro Phenyl, Acquity CSH Phenyl Hexyl and Polaris Amide C18 609 
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[Met(O)10]- and [Met10]-Bovine GLP-2 (1-15) (Peptide Numbers 8 and 1, respectively) were 610 
compared to investigate the effect of oxidation. The more hydrophilic, oxidised methionine eluted 611 
first on all the stationary phases irrespective of the mobile phase conditions, with ample degree of 612 
separation achieved between the two species in either formic acid or ammonium formate gradient 613 
conditions.  614 
 615 
4 Conclusion 616 
A protocol for the characterisation of stationary phases using peptides as probes was successfully 617 
developed.  The protocol utilised two gradient mobile phase systems at low and intermediate pH to 618 
cover different degrees of ionisation of both peptides and stationary phases.  619 
The peptides were rationally designed in order to systematically change characteristics deemed 620 
important for retentivity and selectivity, including hydrophobicity, aromaticity, degree of hydrogen 621 
bonding, electrostatic interactions, steric interactions and important degradation pathways. The 622 
peptides mixtures were injected onto 14 different stationary phases possessing different 623 
chromatographic characteristics, which were grouped into neutral phases (i.e. phases with high 624 
ligand density and a large degree of end-capping), negative character phases (i.e. phases with a 625 
reduced ligand coverage or no end-capping present) and finally positive character phases (i.e. phases 626 
with a positively charged functional group in addition to the RP ligand). Peptides were identified 627 
using SIM, or where differentiation by mass was not possible (i.e. isomers) different peak area ratios 628 
were used. 629 
A range of delta values were calculated which covered the interactions of interest to assess 630 
selectivity differences. The data was analysed using PCA, which highlighted groupings of stationary 631 
phases resembling the three groups described. The number of delta values and peptides were 632 
systematically reduced whilst ensuring that the integrity of the score plot was maintained. 633 
Further evaluation of the data indicated that the most crucial interactions between stationary 634 
phases and peptides are hydrophobic in nature, in combination with polar interactions. These 635 
results, which are based on biologically relevant peptides, suggest that it is polar interactions and 636 
the second order structure of the adsorbed peptide in the stationary phase that to a large extent 637 
contribute to the selectivity and the differences seen between columns. This was highlighted by the 638 
large selectivity differences exhibited for peptides with a similar degree of hydrophobicity. Another 639 
interesting observation was the large selectivity differences exhibited for racemisation species, 640 
which only differ by the orientation of one of the amino acids.  641 
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This first evaluation of the selectivity of peptides will be further investigated and expanded in a 642 
series of articles. The robustness of the protocol will be assessed using systematic changes to the 643 
methodology and practical constraints introduced to ensure the integrity of the methodology. The 644 
protocol will also be applied to a greater array of stationary phases from different column 645 
manufacturers to build a database for rational stationary phase selection for peptide separations 646 
which will be validated with the analysis of tryptic digests of biologically active proteins. In addition, 647 
the results from the database will be compared against small molecule column characterisation data 648 
to ascertain any correlation between the peptide probes and conventional small molecule protocols. 649 
The intention is also to utilise these peptides for the characterisation of a range of mobile phases 650 
employing different pH, ion-pairing additives, organic modifiers and salts.  651 
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7 Figure captions 768 
Fig. 1. Example test mixture containing the two reference peptides used to normalise retention. 769 
Fig. 2. Loading plot of all 66 delta values showing to what extent different delta values contribute to 770 
the two principal components. 771 
Fig. 3. Score plot showing how columns are grouped based on the 66 delta values  772 
Fig. 4. Biplot of the Peptide RPC Column Characterisation Protocol delta values on the 13 stationary 773 
phases. The different stationary phase have been grouped and colour coded based on prior 774 
knowledge of stationary phase properties. 775 
Fig. 5. Biplots of the reduced number of delta values on the 13 stationary phases in (A) formic acid 776 
and (B) TFA. The different stationary phase have been grouped and colour coded based on prior 777 
knowledge of stationary phase properties. 778 
Fig. 6. Sample peak capacity for each column in the score plot measured in formic acid (solid line), 779 
ammonium formate (dotted line) and TFA (dashed line). A large circle indicates a high peak capacity. 780 
Fig. 7. Comparison of (A) Acquity BEH C18 (B) Acquity BEH C8 (C) Acquity BEH C4 (D) Acquity HSS C18 781 
(E) Acquity HSS C18-SB (F) Acquity HSS T3 (G) Acquity CSH C18 (H) Acquity CSH Phenyl Hexyl (I) 782 
Acquity CSH Fluoro Phenyl to investigate hydrophobic interactions (Peptide 13: [Leu26,Ile27]-, 15: 783 
[Ile26,Leu27]-, 20: [Val26,Ile27]-, 21: [Ile26,Ile27]-, 22: [Phe26,Ile27]-, 23: [Trp26,Ile27]-Bovine GLP-2 784 
(16-33)). Data with bars above the retention axis correspond to low pH whereas below the axis 785 
correspond to intermediate pH. 786 
Fig. 8. [Leu26,Ile27]- and [Ile26,Leu27]-Bovine GLP-2 (Peptides 13 and 15) on the Acquity BEH C8 787 
chromatographed using the ammonium formate gradient. 788 
Fig. 9. Comparison of (A) Acquity BEH C18, (B) Acquity CSH C18 (C) Acquity CSH Phenyl Hexyl (D) 789 
Acquity CSH Fluoro Phenyl (E) Polaris Amide C18 (F) Fortis Diphenyl (G) Ascentis Express Biphenyl (H) 790 
Acclaim Mixed Mode WCX (I) Acquity BEH C4 (J) Acquity HSS C18-SB to investigate electrostatic 791 
interactions (Peptide 1: [Asn11]-, 9: [L-Asp11]-Bovine GLP-2 (1-15), 13: [Leu26]-, 26: [Lys26]-Bovine 792 
GLP-2 (16-33)). Data with bars above the retention axis correspond to low pH whereas below the 793 
axis correspond to intermediate pH. 794 
Fig. 10. Comparison of (A) Acquity BEH C18 (B) Fortis Diphenyl (C) Ascentis Express Biphenyl (D) 795 
Acquity CSH Fluoro Phenyl (E) Acquity CSH C18 (F) Acquity CSH Phenyl Hexyl to investigate aromatic 796 
interactions (Peptide 13: [Leu26]-, 22: [Phe26]-, 23: [Trp26]-, 24: [Tyr26]-Bovine GLP-2 (16-33)). Data 797 
with bars above the retention axis correspond to low pH whereas below the axis correspond to 798 
intermediate pH. 799 
27 
Fig. 11. Chromatograms of (13) [L-Ser16]- and (14) [D-Ser16]-Bovine GLP-2 (16-33) on phases 800 
predicted to be similar or dissimilar based on the biplot in Fig. 4. From L-R: Acquity HSS C18-SB, 801 
Acquity CSH Phenyl Hexyl, Acquity HSS T3, Acquity BEH C18, A-D in formic acid, E-H in ammonium 802 
formate. 803 
Table 1  
Stationary phase used in the development of the Peptide RPC Column Characterisation Protocol and their physical parameters 
Manufacturer Column Pore Size (Å) Particle Size (µm) Description 
Waters Acquity UPLC BEH C4 300 1.7 A non endcapped, trifunctional C4 alkyl ligand bonded to ethyl bridged silica hybrid material 
Waters Acquity BEH C8 130 1.7 An endcapped, trifunctional C8 alkyl ligand bonded to ethyl bridged silica hybrid material 
Waters Acquity UPLC BEH C18 130 1.7 An endcapped, trifunctional C18 alkyl ligand bonded to ethyl bridged silica hybrid material 
Waters Acquity BEH Shield RP18 130 1.7 
An endcapped, monofunctional alkyl ligand with an embedded carbamide functionality 
bonded to ethyl bridged silica hybrid material 
Waters Acquity CSH C18 130 1.7 
An endcapped, trifunctional C18 alkyl ligand bonded to ethyl bridged silica hybrid material 
which possesses a low level positive surface charge 
Waters Acquity CSH Fluoro Phenyl 130 1.7 
A non endcapped, trifunctional pentafluorophenyl moiety ligand bonded to ethyl bridged 
silica hybrid material which possesses a low level positive surface charge 
Waters Acquity CSH Phenyl Hexyl 130 1.7 
An endcapped, trifunctional C6 alkyl chain with a terminal phenyl functionality bonded to 
ethyl bridged silica hybrid material which possesses a low level positive surface charge 
Waters Acquity HSS C18 100 1.8 An endcapped, trifunctional C18 alkyl ligand 
Waters Acquity HSS C18 SB 100 1.8 A non endcapped, trifunctional C18 alkyl phase with low ligand density 
Waters Acquity HSS T3 100 1.8 
An endcapped, trifunctional, 100% aqueous compatible C18 alkyl phase with reduce ligand 
density 
Agilent Polaris Amide C18 180 3 
An endcapped, monofunctional alkyl ligand with an embedded amide functionality which 
possesses positive character due to residual amino groups related to a two step synthetic 
process 
Supelco Ascentis Express Biphenyl 90 2.7 An endcapped, superficially porous particle with a biphenyl ligand 
Fortis Fortis Diphenyl 100 1.7 An endcapped, diphenyl ligand  
Thermo Acclaim Mixed Mode WCX 120 3 A mixed mode ligand composed of an alkyl chain with carboxylic acid terminus 
 
  
Table 2 
Peptide sequence of Bovine GLP-2 
 
Amino Acid # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 
Bovine GLP-2 H A D G S F S D E M N T V L D S L A T R D F I N W L I Q T K I T D 
 
  
Table 3  
List of peptides used to develop the Peptide RPC Column Characterisation protocol and their rationale* 
Peptide 
Number 
Peptide Rationale pI LogP 
Net Charge Sequence 
pH 2.5 pH 6.5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 
1 Bovine GLP-2 (1-15) Original sequence 3.9 -12.18 1.2 -3.7 H A D G S F S D E M N T V L D                   
2 [D-His1]-Bovine GLP-2 (1-15) Racemisation 3.9 -12.18 1.2 -3.7 h A D G S F S D E M N T V L D                   
3 [D-Asp3]-Bovine GLP-2 (1-15) Racemisation 3.7 -12.18 1.2 -3.7 H A d G S F S D E M N T V L D                   
4 [L-isoAsp3]-Bovine GLP-2 (1-15) Isomerisation 3.7 -12.18 1.2 -3.7 H A iD G S F S D E M N T V L D                   
5 [D-isoAsp3]-Bovine GLP-2 (1-15) Racemisation / Isomerisation 3.7 -12.18 1.2 -3.7 H A id G S F S D E M N T V L D                   
6 [D-Ser5]-Bovine GLP-2 (1-15) Racemisation 3.9 -12.18 1.2 -3.7 H A D G s F S D E M N T V L D                   
7 [D-Ser7]-Bovine GLP-2 (1-15) Racemisation 3.9 -12.18 1.2 -3.7 H A D G S F s D E M N T V L D                   
8 [Met(O)10]-Bovine GLP-2 (1-15) Oxidation 3.9 -12.18 1.2 -3.7 H A D G S F S D E oM N T V L D                   
9 [L-Asp11]-Bovine GLP-2 (1-15) Deamidation / Negative charge 3.6 -11.55 1.1 -4.7 H A D G S F S D E M D T V L D                   
10 [D-Asp11]-Bovine GLP-2 (1-15) 
Deamidation / Racemisation / 
Negative charge 
3.6 -11.55 1.1 -4.7 
H A D G S F S D E M d T V L D                   
11 [L-isoAsp11]-Bovine GLP-2 (1-15) 
Deamidation / Isomerisation / 
Negative charge 
3.6 -11.55 1.1 -4.7 
H A D G S F S D E M iD T V L D                   
12 [D-isoAsp11]-Bovine GLP-2 (1-15) 
Deamidation / Isomerisation / 
Racemisation / Negative charge 
3.6 -11.55 1.1 -4.7 
H A D G S F S D E M id T V L D                   
13 Bovine GLP-2 (16-33) Original sequence 5.4 -10.21 2.2 0.0                S L A T R D F I N W L I Q T K I T D 
14 [D-Ser16]-Bovine GLP-2 (16-33) Racemisation 5.4 -10.21 2.2 0.0                s L A T R D F I N W L I Q T K I T D 
15 [Ile26,Leu27]-Bovine GLP-2 (16-33) Switch in AA sequence 5.4 -10.21 2.2 0.0                S L A T R D F I N W I L Q T K I T D 
16 [L-Asp21,Gly22]-Bovine GLP-2 (16-33) Loss of aromatic group 5.4 -10.21 2.2 0.0                S L A T R D G I N W L I Q T K I T D 
17 [D-Asp21,Gly22]-Bovine GLP-2 (16-33) Loss of aromatic group / Racemisation 5.4 -10.21 2.2 0.0                S L A T R d G I N W L I Q T K I T D 
18 [L-isoAsp21,Gly22]-Bovine GLP-2 (16-33) Loss of aromatic group / Isomerisation 5.3 -12.24 2.2 0.0                S L A T R iD G I N W L I Q T K I T D 
19 [D-isoAsp21,Gly22]-Bovine GLP-2 (16-33) 
Loss of aromatic group / Racemisation 
/ Isomerisation 
5.3 -12.24 2.2 0.0 
               S L A T R id G I N W L I Q T K I T D 
20 [Val26]-Bovine GLP-2 (16-33) Steric / Aliphatic effect 5.4 -10.59 2.2 0.0                S L A T R D F I N W V I Q T K I T D 
21 [Ile26]-Bovine GLP-2 (16-33) Steric / Aliphatic effect 5.4 -10.14 2.2 0.0                S L A T R D F I N W I I Q T K I T D 
22 [Phe26]-Bovine GLP-2 (16-33) Aromatic effect 5.4 -9.88 2.2 0.0                S L A T R D F I N W F I Q T K I T D 
23 [Trp26]-Bovine GLP-2 (16-33) Aromatic effect 5.4 -9.59 2.2 0.0                S L A T R D F I N W W I Q T K I T D 
24 [Tyr26]-Bovine GLP-2 (16-33) Aromatic / Phenolic effect 5.4 -10.12 2.2 0.0                S L A T R D F I N W Y I Q T K I T D 
25 [Lys20]-Bovine GLP-2 (16-33) Polarity effect 5.4 -12.09 2.2 0.0                S L A T K D F I N W L I Q T K I T D 
26 [Lys26]-Bovine GLP-2 (16-33) Positive charge 8.2 -13.99 3.2 1.0                S L A T R D F I N W K I Q T K I T D 
*d corresponds to D-Asp, iD to L-isoAsp, id to D-isoAsp, h and s corresponds to D-His and D-Ser respectively and oM corresponds to Met(O). 
 
Table 4  
List of delta values, their rationale and the average Δtg and Δtg* in formic acid, TFA or ammonium formate 
Delta Change Rationale 
Average Δtg 
in FA (min) 
Average Δtg* 
in FA (-) 
Average Δtg 
in TFA (min) 
Average Δtg* 
in TFA (-) 
Average Δtg 
in AF (min) 
Average Δtg* 
in AF (-) 
Δ(2,1) [L-His1] → [D-His1] Steric - racemisation 0.091 0.009   0.315 0.016 
Δ(3,1) [L-Asp3] → [D-Asp3] Steric - racemisation -0.026 0.004   -0.076 -0.001 
Δ(4,1) [L-Asp3] → [L-isoAsp3] Increase in negative charge 0.078 0.016   -0.263 -0.008 
Δ(5,1) [L-Asp3] → [D-isoAsp3] Increase in negative charge 0.395 0.038   0.049 0.006 
Δ(5,4) [L-isoAsp3] → [D-isoAsp3] Steric - racemisation 0.317 0.022   0.311 0.014 
Δ(6,1) [L-Ser5] → [D-Ser5] Steric - racemisation 0.006 0.008   0.283 0.016 
Δ(7,1) [L-Ser7] → [D-Ser7] Steric - racemisation  -0.619 -0.036   -0.051 0.002 
Δ(8a,1)* [Met10] → [Met(O)10] Oxidation -4.166 -0.289 -3.655 -0.278 -3.598 -0.157 
Δ(8b,1)* [Met10] → [Met(O)10] Oxidation -4.085 -0.283   -3.542 -0.154 
Δ(8b,8a)* [Met(O)10] → [Met(O)10] Steric - racemisation 0.081 0.006   0.056 0.003 
Δ(9,1) [L-Asn11] → [L-Asp11] Increase in negative charge 0.802 0.059 0.583 0.044 -1.142 -0.055 
Δ(10,1) [L-Asn11] → [D-Asp11] Increase in negative charge 0.575 0.044   -1.786 -0.083 
Δ(10,9) [L-Asp11] → [D-Asp11] Steric - racemisation -0.228 -0.016   -0.644 -0.028 
Δ(11,1) [L-Asn11] → [L-isoAsp11] Increase in negative charge -1.232 -0.078   -2.569 -0.115 
Δ(12,1) [L-Asn11] → [D-isoAsp11] Increase in negative charge -0.648 -0.038   -2.148 -0.098 
Δ(12,11) [L-isoAsp11] → [D-isoAsp11] Steric - racemisation 0.584 0.040   0.421 0.017 
Δ(14,13) [L-Ser16] → [D-Ser16] Steric - racemisation -0.100 0.007 -0.167 -0.013 0.297 0.011 
Δ(15,13) [Leu26,Ile27] → [Ile26,Leu27] Steric – switch in amino acid sequence 0.491 0.047 0.443 0.033 1.118 0.049 
Δ(16,13) [L-Asp21,Phe22] → [L-Asp21,Gly22] Aromatic – removal of aromatic group -5.927 -0.404 -4.425 -0.329 -7.037 -0.312 
Δ(17,16) [L-Asp21,Gly22] → [D-Asp21,Gly22] Steric - racemisation 0.129 -0.004   0.929 0.038 
Δ(18,16) [L-Asp21,Gly22] → [L-isoAsp21,Gly22] Increase in negative charge 0.652 0.036   1.122 0.052 
Δ(19,16) [L-Asp21,Gly22] → [D-isoAsp21,Gly22] Increase in negative charge 0.421 0.017   0.902 0.044 
Δ(19,18) [L-isoAsp21,Gly22] → [D-isoAsp21,Gly22] Steric - racemisation -0.231 -0.019   -0.220 -0.009 
Δ(20,13) [Leu26] → [Val26] Alkyl – removal of -CH2 -2.025 -0.117   -1.745 -0.075 
Δ(21,13) [Leu26] → [Ile26] Alkyl – change of -CH3 position -0.924 -0.033   -0.456 -0.018 
Δ(22,13) [Leu26] → [Phe26] Aromatic – addition of aromatic group -0.803 -0.023   -0.338 -0.014 
Δ(23,13) [Leu26] → [Trp26] Aromatic – addition of aromatic group -1.201 -0.056   -0.962 -0.039 
Δ(23,22) [Phe26] → [Trp26] Aromatic – addition of aromatic group -0.398 -0.032   -0.624 -0.025 
Δ(24,13) [Leu26] → [Tyr26] Phenolic – addition of hydroxyl group -3.648 -0.236 -2.791 -0.210 -3.835 -0.164 
Δ(24,22) [Phe26] → [Tyr26] Phenolic – addition of hydroxyl group -2.844 -0.212   -3.497 -0.151 
Δ(24,23) [Trp26] → [Tyr26] Phenolic – addition of hydroxyl group -2.447 -0.180   -2.873 -0.126 
Δ(25,13) [Arg20] → [Lys20] Change in polarity -0.767 -0.012   -0.116 -0.004 
Δ(26,13) [Leu26] → [Lys26] Increase in positive charge -8.213 -0.587 -5.926 -0.457 -6.773 -0.279 
*a and b corresponds to the first and last eluting isomer of [Met(O)10]-Bovine GLP-2 (1-15) 
NB The sign prior to the Δtg* in mins indicates the elution order e.g. [Leu26] → [Lys26] with a Δtg of -8.213 means that [Lys26] elutes earlier than [Leu26] 
 
  
Table 5  
Final test mixtures used for the Peptide RPC Column Characterisation Protocol 
Test Mixture Delta Measured in Formic Acid Measured in Ammonium Formate 
TM1 Δ(8a,1)* ✓  
TM1 Δ(9,1) ✓ ✓ 
TM1 Δ(15,13)  ✓ 
TM1 Δ(16,13) ✓  
TM1 Δ(24,13)  ✓ 
TM2 Δ(10,9)  ✓ 
TM2 Δ(26,13) ✓ ✓ 
TM3 Δ(3,1)  ✓ 
TM3 Δ(14,13) ✓  
*a corresponds to the first eluting isomer of [Met(O)10]-Bovine GLP-2 (1-15) 
 
  
Table 6  
Peak capacity measured for each stationary phase using both the formic acid, TFA and ammonium formate gradients 
PC** 
Acquity BEH 
C4 
Acquity BEH 
C8 
Acquity BEH 
C18 
Acquity BEH 
Shield RP-18 
Acquity CSH 
C18 
Acquity CSH 
Fluoro Phenyl 
Acquity CSH 
Phenyl Hexyl 
Acquity HSS 
C18 
Acquity HSS 
C18-SB 
Acquity HSS 
T3 
Ascentis 
Express 
Biphenyl 
Fortis 
Diphenyl 
Polaris Amide 
C18 
Formic Acid 90 121 123 137 146 78 108 80 108 64 66 66 79 
Trifluoroacetic 
Acid 
172 137 174 168 173 140 147 142 68 81 129 130 108 
Ammonium 
Formate 129 212 222 229 196 124 180 173 81 183 193 122 96 
 
7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 min
tgRef1 tgRef2
Δ(2,1) FA
Δ(10,1) AF
Δ(14,13) AF
Δ(6,1) AF
Δ(5,4) FA
Δ(14,13) FA
Δ(25,13) FA
Δ(12,1) AF
Δ(10,9) AF
Δ(25,13) AF
Δ(21,13) FA
Δ(15,13) AF
Δ(2,1) AF
Δ(4,1) AF
Δ(3,1) AF
Δ(16,13) AF
Δ(18,16) FA Δ(5,1) FA
Δ(19,16) FAΔ(4,1) FA
Δ(19,18) FA Δ(9,1) FA
Δ(6,1) FA
Δ(11,1) FA
Δ(16,13) FA
Δ(26,13) FA
Δ(3,1) FA
Δ(20,13) FA
Δ(19,18) AF
Δ(21,13) AF Δ(12,11) FA
Δ(24,22) FA Δ(23,22) FA Δ(12,1) FA
Δ(5,1) AF
Δ(18,16) AF
Δ(19,16) AF
Δ(5,4) AF
Δ(17,16) AF
Δ(24,22) AFΔ(23,13) AF
Δ(22,13) AF Δ(23,13) FA
Δ(24,13) AF
Δ(24,13) FA
Δ(24,13) FA
Δ(26,13) AF
Δ(8a,1) FA
Δ(8b,1) FA
Δ(10,9) FA
Δ(22,13) FA
Δ(20,13) AF
Δ(8a,1) AF
Δ(8b,1) AFΔ(7,1) FA
Δ(17,16) FA
Δ(12,11) AF
Δ(24,23) FA
Δ(8b,8a) AF
Δ(15,13) FA
Δ(11,1) AF
Δ(9,1) AF
Δ(8b,8a) FA
Δ(7,1) AF Δ(10,1) FAΔ(23,22) AF
Delta Value Character
Alkyl
Aromatic
Negative charge
Oxidation
Phenolic
Positive charge
Steric
Stationary Phase Character
Acquity CSH Fluoro Phenyl
Acquity CSH Phenyl Hexyl
Polaris Amide C18
Acquity CSH C18
Acquity BEH C4
Acquity BEH C8
Acquity HSS T3
Acquity HSS C18-SB
Ascentis Express Biphenyl
Acquity BEH Shield RP-18
Fortis Diphenyl
Acquity HSS C18
Acquity BEH C18
Delta Value Character
Stationary Phase Character
Δ(16,13) FA
Δ(3,1) AF
Δ(26,13) FA
Δ(24,13) AF
Δ(15,13) AF
Δ(9,1) AF
Δ(9,1) FA
Δ(14,13) FA
Δ(26,13) AF
Δ(8a,1) FA
Δ(10,9) AF
Acquity HSS C18-SB
Ascentis Express Biphenyl
Acquity BEH Shield RP-18
Fortis Diphenyl
Acquity HSS C18
Acquity BEH C4
Acquity BEH C18
Acquity BEH C8
Acquity HSS T3
Acquity CSH Fluoro Phenyl
Acquity CSH C18
Acquity CSH Phenyl Hexyl
Polaris Amide C18
FA all probes
Delta Value Character
Stationary Phase Character
Δ(16,13) FA
Δ(26,13) FA
Δ(9,1) FA
Δ(14,13) FA
Δ(8a,1) FA
Acquity HSS C18
Acquity BEH C8
Acquity HSS T3
Acquity CSH Fluoro Phenyl
Acquity CSH Phenyl Hexyl
Acquity HSS C18-SB
Δ(15,13) FA
Ascentis Express Biphenyl
Polaris Amide C18
Fortis Diphenyl
A
Δ(24,13) FA 
Acquity BEH C4
Acquity CSH C18
Acquity BEH Shield RP-18
Acquity BEH C18
TFA all probes
Delta Value Character
Stationary Phase Character
Δ(16,13) TFA
Δ(26,13) TFA
Δ(24,13) TFA
Δ(9,1) TFA
Δ(14,13) TFA
Δ(8a,1) TFA
Acquity HSS C18
Acquity BEH C4
Acquity BEH C8
Acquity HSS T3
Acquity CSH Fluoro Phenyl
Acquity CSH Phenyl Hexyl
Acquity BEH Shield RP-18
Acquity HSS C18-SB
Acquity BEH C18
Δ(15,13) TFA
Acquity CSH C18
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